Master End-to-End AI for Drug Discovery, Delivery, and Biological Validation in 4 weeks through hands-on, project-based online training with DSTC.
This course introduces an end-to-end AI workflow for therapeutic innovation, beginning with target and compound selection, moving through drug delivery and formulation design, and ending with biological validation strategies. Across 4 Weeks, you will work hands-on with drug delivery and formulation design, then consolidate everything in a capstone project. Every participant receives a verified e-Certificate and e-Marksheet from the Deep Science & Technology Consortium.
This course introduces an end-to-end AI workflow for therapeutic innovation, beginning with target and compound selection, moving through drug delivery and formulation design, and ending with biological validation strategies.
1. Gain working command of drug delivery.
2. Develop hands-on skill in formulation design.
3. Apply biotechnology methods to authentic research and industry problems.
4. Assemble a documented case study that evidences your applied capability.
β’ Master's and senior undergraduate students specializing in biotechnology
β’ R&D engineers and working professionals applying biotechnology in industry
β’ Academics and educators building research or teaching capacity in biotechnology
β’ Data and computational scientists moving into drug delivery
β’ Confidence to apply drug delivery in real projects.
β’ Confidence to implement formulation design in real projects.
β’ A portfolio-grade biotechnology deliverable you can defend and extend.
β’ A verified e-Certificate of competency and e-Marksheet from the Deep Science & Technology Consortium.
β’ Target identification from Open Targets and genetic evidence for tractability
β’ Genetic support roughly doubles clinical success β how to use that in practice
β’ Distinguishing a druggable target from a merely disease-associated one
β’ Virtual screening and property prediction placed in the discovery timeline
β’ Multi-parameter optimisation: potency, selectivity and ADMET traded off together
β’ Why single-objective optimisation reliably produces undevelopable compounds
β’ Solubility, permeability and BCS classification driving formulation choice
β’ Nanoparticle and lipid-nanoparticle systems, and ML for formulation parameters
β’ Release profile modelling and the gap between in vitro and in vivo behaviour
β’ Assay design, controls and the statistical power an in vitro screen actually needs
β’ Cell line, organoid and animal models ranked by translational relevance
β’ Orthogonal assays as the standard defence against a target-engagement artefact
β’ Where AI genuinely compresses the timeline and where it does not
β’ Data capture and versioning so predictions can be audited later
β’ Go / no-go criteria set in advance rather than argued after the result
| Parameter | Requirement |
|---|---|
| Covered Tool / Platform | AutoDock Vina |
| Covered Tool / Platform | PyRx |
| Covered Tool / Platform | SchrΓΆdinger Suite |
| Covered Tool / Platform | GROMACS |
| Covered Tool / Platform | ChemDraw |
| Covered Tool / Platform | Discovery Studio |
| Covered Tool / Platform | ADMET Predictor |
Based on 0 scholar submissions
No verified reviews published yet. Be the first to share your academic experience.
Your rating will help prospective scholars. Ratings below 3 stars are routed privately to the faculty mentor for immediate response.